Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Neurons under genetic control: What are the next steps towards the treatment of movement disorders?. Local targets link to admitted publications; unresolved targets remain external evidence.
Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease
1987 · External reference
Suppression of intention tremor by contingent deep-brain stimulation
10.1016/s0140-6736(80)91680-3 · 1980 · External reference
10.3171/2010.4.focus10106
10.3171/2010.4.focus10106 · External reference
Deep brain stimulation: foundations and future trends
10.2741/4586 · 2018 · External reference
Drug therapy in patients with Parkinson's disease
10.1186/2047-9158-1-10 · 2012 · External reference
Surgical approach to l-dopa-induced dyskinesias
10.1016/b978-0-12-381328-2.00006-7 · 2011 · External reference
Deep brain stimulation of the globus pallidus pars interna in advanced Parkinson's disease
2000 · External reference
Long-term outcomes following deep brain stimulation for Parkinson's disease
2019 · External reference
“On-off” effects in patients with Parkinson's disease on chronic levodopa therapy
10.1016/s0140-6736(76)91416-1 · 1976 · External reference
Stalevo reduction in dyskinesia evaluation in parkinson's disease, factors predictive of the development of levodopa-induced dyskinesia and wearing-off in Parkinson's disease
10.1002/mds.25364 · 2013 · External reference
Pallidal neurostimulation in patients with medication-refractory cervical dystonia: a randomised, sham-controlled trial
10.1016/s1474-4422(14)70143-7 · 2014 · External reference
French Stimulation for Tardive dyskinesia study, bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia
10.1001/archpsyc.64.2.170 · 2007 · External reference
Short and long term outcome of bilateral pallidal stimulation in chorea-acanthocytosis
10.1371/journal.pone.0079241 · 2013 · External reference
Bilateral pallidal deep brain stimulation for the treatment of patients with dystonia-choreoathetosis cerebral palsy: a prospective pilot study
10.1016/s1474-4422(09)70151-6 · 2009 · External reference
10.1212/wnl.0000000000004295
10.1212/wnl.0000000000004295 · External reference
Surgical approaches working group of the european Huntington's disease, a prospective pilot trial for pallidal deep brain stimulation in huntington's disease
10.3389/fneur.2015.00177 · 2015 · External reference
Acute changes in mood induced by subthalamic deep brain stimulation in Parkinson disease are modulated by psychiatric diagnosis
10.1016/j.brs.2014.06.002 · 2014 · External reference
Impulse control behaviors and subthalamic deep brain stimulation in Parkinson disease
10.1007/s00415-016-8314-x · 2017 · External reference
Functional movement disorders arising after successful deep brain stimulation
10.1212/wnl.0000000000005530 · 2018 · External reference
10.1038/nn1525
10.1038/nn1525 · External reference
10.1016/j.neuron.2009.03.011
10.1016/j.neuron.2009.03.011 · External reference
10.1371/journal.pone.0002005
10.1371/journal.pone.0002005 · External reference
10.1038/nrn3171
10.1038/nrn3171 · External reference
10.1016/j.neuron.2009.07.016
10.1016/j.neuron.2009.07.016 · External reference
10.1038/nrn2886
10.1038/nrn2886 · External reference
10.1038/nn.3950
10.1038/nn.3950 · External reference
10.1152/jn.01170.2005
10.1152/jn.01170.2005 · External reference
10.1152/jn.00245.2003
10.1152/jn.00245.2003 · External reference
10.1016/j.neuron.2008.01.002
10.1016/j.neuron.2008.01.002 · External reference
10.1038/nrn2192
10.1038/nrn2192 · External reference
Uncovering the mechanism(s) of action of deep brain stimulation: activation, inhibition, or both
10.1016/j.clinph.2003.12.024 · 2004 · External reference
High frequency deep brain stimulation: what are the therapeutic mechanisms?
10.1016/j.neubiorev.2006.10.007 · 2008 · External reference
10.1177/1073858415581986
10.1177/1073858415581986 · External reference
The clinical utility of methods to determine spatial extent and volume of tissue activated by deep brain stimulation
10.1016/j.clinph.2008.06.003 · 2008 · External reference
10.1001/2013.jamaneurol.45
10.1001/2013.jamaneurol.45 · External reference
10.1152/jn.00281.2015
10.1152/jn.00281.2015 · External reference
Deep brain stimulation in Huntington's disease-preliminary evidence on pathophysiology, efficacy and safety
10.3390/brainsci6030038 · 2016 · External reference
10.1016/j.cobme.2018.08.008
10.1016/j.cobme.2018.08.008 · External reference
10.1523/jneurosci.4144-11.2013
10.1523/jneurosci.4144-11.2013 · External reference
Selective attenuation of afferent synaptic transmission as a mechanism of thalamic deep brain stimulation-induced tremor arrest
10.1523/jneurosci.3523-05.2006 · 2006 · External reference
10.1111/j.1460-9568.2010.07413.x
10.1111/j.1460-9568.2010.07413.x · External reference
10.1111/jnc.13649
10.1111/jnc.13649 · External reference
10.1038/nrneurol.2017.105
10.1038/nrneurol.2017.105 · External reference
Mechanisms of deep brain stimulation and future technical developments
10.1080/01616412.2000.11740668 · 2000 · External reference
10.1038/s41582-018-0128-2
10.1038/s41582-018-0128-2 · External reference
Patterning of globus pallidus local field potentials differs between Parkinson's disease and dystonia
10.1093/brain/awg267 · 2003 · External reference
A model of desynchronizing deep brain stimulation with a demand-controlled coordinated reset of neural subpopulations
10.1007/s00422-003-0425-7 · 2003 · External reference
10.1371/journal.pcbi.1006113
10.1371/journal.pcbi.1006113 · External reference
Periodic flashing coordinated reset stimulation paradigm reduces sensitivity to ON and OFF period durations
10.1371/journal.pone.0203782 · 2018 · External reference
10.1016/0166-2236(89)90074-x
10.1016/0166-2236(89)90074-x · External reference
Microcircuitry of the direct and indirect pathways of the basal ganglia
1998 · External reference
10.1101/cshperspect.a009621
10.1101/cshperspect.a009621 · External reference
10.1152/jn.2000.83.3.1760
10.1152/jn.2000.83.3.1760 · External reference
10.1523/jneurosci.3834-08.2008
10.1523/jneurosci.3834-08.2008 · External reference
10.3389/fnsys.2011.00089
10.3389/fnsys.2011.00089 · External reference
Cortically evoked responses of human pallidal neurons recorded during stereotactic neurosurgery
10.1002/mds.23502 · 2011 · External reference
10.1523/jneurosci.1278-13.2013
10.1523/jneurosci.1278-13.2013 · External reference
10.1038/nature11846
10.1038/nature11846 · External reference
10.1038/nn.3743
10.1038/nn.3743 · External reference
10.1146/annurev-neuro-072116-031033
10.1146/annurev-neuro-072116-031033 · External reference
10.1126/science.1167093
10.1126/science.1167093 · External reference
10.1038/nature09159
10.1038/nature09159 · External reference
10.1016/j.neuron.2017.08.028
10.1016/j.neuron.2017.08.028 · External reference
10.1038/nn.4559
10.1038/nn.4559 · External reference
10.1523/jneurosci.3539-10.2011
10.1523/jneurosci.3539-10.2011 · External reference
Multiple sources of striatal inhibition are differentially affected in Huntington's disease mouse models
10.1523/jneurosci.2137-12.2013 · 2013 · External reference
10.1007/s10827-009-0196-9
10.1007/s10827-009-0196-9 · External reference
10.1016/s1474-4422(08)70223-0
10.1016/s1474-4422(08)70223-0 · External reference
10.1126/science.8351520
10.1126/science.8351520 · External reference
10.1016/0165-0270(95)00085-2
10.1016/0165-0270(95)00085-2 · External reference
Unresolved reference
External reference
10.1038/416433a
10.1038/416433a · External reference
10.1126/science.275.5297.213
10.1126/science.275.5297.213 · External reference
10.1038/nn.3970
10.1038/nn.3970 · External reference
Closed-loop deep brain stimulation by pulsatile delayed feedback with increased gap between pulse phases
10.1038/s41598-017-01067-x · 2017 · External reference
Sensorimotor rhythm neurofeedback as adjunct therapy for Parkinson's disease
10.1002/acn3.434 · 2017 · External reference
10.1007/s13311-014-0280-3
10.1007/s13311-014-0280-3 · External reference
10.1016/j.neuron.2011.08.023
10.1016/j.neuron.2011.08.023 · External reference
The adaptive deep brain stimulation challenge
10.1016/j.parkreldis.2016.03.020 · 2016 · External reference
10.1002/ana.23951
10.1002/ana.23951 · External reference
Gamma oscillations in the hyperkinetic state detected with chronic human brain recordings in Parkinson's disease
10.1523/jneurosci.1128-16.2016 · 2016 · External reference
Adaptive deep brain stimulation for Parkinson's disease using motor cortex sensing
10.1088/1741-2552/aabc9b · 2018 · External reference
10.1038/s41592-018-0183-z
10.1038/s41592-018-0183-z · External reference
10.1038/nature06310
10.1038/nature06310 · External reference
10.1093/hmg/ddp475
10.1093/hmg/ddp475 · External reference
Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates
10.1038/mt.2009.216 · 2010 · External reference
Effects on capacitance by overexpression of membrane proteins
10.1016/j.bbrc.2008.02.153 · 2008 · External reference
10.1016/j.neuron.2011.06.004
10.1016/j.neuron.2011.06.004 · External reference
10.1016/s0140-6736(07)60982-9
10.1016/s0140-6736(07)60982-9 · External reference
10.1089/hum.2009.182
10.1089/hum.2009.182 · External reference
Comparison of transduction efficiency of recombinant AAV serotypes 1, 2, 5, and 8 in the rat nigrostriatal system
10.1111/j.1471-4159.2009.06010.x · 2009 · External reference
10.1146/annurev-bioeng-071813-104938
10.1146/annurev-bioeng-071813-104938 · External reference
Cell-mediated immunity to AAV vectors, evolving concepts and potential solutions
10.3389/fimmu.2014.00350 · 2014 · External reference
AAV8 induces tolerance in murine muscle as a result of poor APC transduction, T cell exhaustion, and minimal MHCI upregulation on target cells
10.1038/mt.2013.134 · 2014 · External reference
10.1038/gt.2015.109
10.1038/gt.2015.109 · External reference
10.1182/blood-2013-01-306647
10.1182/blood-2013-01-306647 · External reference
Mapping the AAV capsid host antibody response toward the development of second generation gene delivery vectors
10.3389/fimmu.2014.00009 · 2014 · External reference
Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles
10.1128/jvi.00675-12 · 2012 · External reference
10.3389/fmicb.2011.00204
10.3389/fmicb.2011.00204 · External reference
Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union
10.1038/mt.2012.194 · 2012 · External reference
10.1016/s0140-6736(16)30371-3
10.1016/s0140-6736(16)30371-3 · External reference
Voretigene neparvovec: a review in RPE65 mutation-associated inherited retinal dystrophy
10.1007/s40291-020-00475-6 · 2020 · External reference
10.1016/s0140-6736(17)31868-8
10.1016/s0140-6736(17)31868-8 · External reference
10.1016/s1474-4422(11)70039-4
10.1016/s1474-4422(11)70039-4 · External reference
10.1007/s40259-017-0234-5
10.1007/s40259-017-0234-5 · External reference
10.1523/jneurosci.1839-17.2017
10.1523/jneurosci.1839-17.2017 · External reference
10.1152/jn.00153.2013
10.1152/jn.00153.2013 · External reference
10.1117/1.nph.2.3.031202
10.1117/1.nph.2.3.031202 · External reference
10.1038/nn.2749
10.1038/nn.2749 · External reference
10.1038/nn.3210
10.1038/nn.3210 · External reference
10.1016/j.neuron.2012.10.016
10.1016/j.neuron.2012.10.016 · External reference
10.1016/j.cub.2012.07.023
10.1016/j.cub.2012.07.023 · External reference
10.1038/nmeth.2996
10.1038/nmeth.2996 · External reference
10.1016/j.sbi.2019.04.003
10.1016/j.sbi.2019.04.003 · External reference
10.1016/j.celrep.2019.02.011
10.1016/j.celrep.2019.02.011 · External reference
10.1038/s41467-020-16046-6
10.1038/s41467-020-16046-6 · External reference
Primate optogenetics: Progress and prognosis
10.1073/pnas.1902284116 · 2019 · External reference
10.1016/j.cell.2016.08.024
10.1016/j.cell.2016.08.024 · External reference
10.1126/science.1193771
10.1126/science.1193771 · External reference
Medial septum regulates the hippocampal spatial representation
10.3389/fnbeh.2015.00166 · 2015 · External reference
10.1016/j.neuron.2013.08.023
10.1016/j.neuron.2013.08.023 · External reference
10.1016/j.neuron.2011.10.028
10.1016/j.neuron.2011.10.028 · External reference
10.1371/journal.pbio.2002365
10.1371/journal.pbio.2002365 · External reference
10.1088/1741-2560/4/3/s02
10.1088/1741-2560/4/3/s02 · External reference
Prosthetic systems for therapeutic optical activation and silencing of genetically-targeted neurons
2008 · External reference
Subthalamic nucleus volumes are highly consistent but decrease age-dependently-a combined magnetic resonance imaging and stereology approach in humans
10.1002/hbm.23427 · 2017 · External reference
10.1016/j.jneumeth.2012.08.004
10.1016/j.jneumeth.2012.08.004 · External reference
FEF inactivation with improved optogenetic methods
10.1073/pnas.1610784113 · 2016 · External reference
Modulation of physiological brain hyperthermia by environmental temperature and impaired blood outflow in rats
10.1016/j.physbeh.2004.08.032 · 2004 · External reference
Brain hyperthermia during physiological and pathological conditions: causes, mechanisms, and functional implications
10.2174/1567202043480233 · 2004 · External reference
10.1038/nn.3752
10.1038/nn.3752 · External reference
10.1038/nature10360
10.1038/nature10360 · External reference
10.1038/nmeth.2836
10.1038/nmeth.2836 · External reference
10.1038/nature15389
10.1038/nature15389 · External reference
CRISPR/Cas9: a powerful genetic engineering tool for establishing large animal models of neurodegenerative diseases
10.1186/s13024-015-0031-x · 2015 · External reference
Editing the central nervous system through CRISPR/Cas9 systems
10.3389/fnmol.2019.00110 · 2019 · External reference
10.1038/nmeth.2649
10.1038/nmeth.2649 · External reference
10.1038/nbt.2842
10.1038/nbt.2842 · External reference
10.1126/science.1254445
10.1126/science.1254445 · External reference
Emerging genetic therapies to treat Duchenne muscular dystrophy
10.1097/wco.0b013e32832fd487 · 2009 · External reference
10.1038/ncomms14454
10.1038/ncomms14454 · External reference
10.1016/j.ymthe.2018.08.019
10.1016/j.ymthe.2018.08.019 · External reference
Permanent inactivation of Huntington's disease mutation by personalized allele-specific CRISPR/Cas9
2016 · External reference
CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington's disease
10.1172/jci92087 · 2017 · External reference
10.1016/j.cell.2014.05.010
10.1016/j.cell.2014.05.010 · External reference
10.1038/s41591-018-0326-x
10.1038/s41591-018-0326-x · External reference
10.1146/annurev-biochem-010909-095056
10.1146/annurev-biochem-010909-095056 · External reference
10.1016/j.neuroscience.2008.11.024
10.1016/j.neuroscience.2008.11.024 · External reference
10.1038/s41591-019-0478-3
10.1038/s41591-019-0478-3 · External reference
10.1016/s1474-4422(17)30280-6
10.1016/s1474-4422(17)30280-6 · External reference
Deimmunization for gene therapy: host matching of synthetic zinc finger constructs enables long-term mutant Huntingtin repression in mice
10.1186/s13024-016-0128-x · 2016 · External reference
10.1038/35888
10.1038/35888 · External reference
Gene suppression approaches to neurodegeneration
10.1186/s13195-017-0307-1 · 2017 · External reference
RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs
10.3390/cells9010137 · 2020 · External reference
10.1038/nrm2321
10.1038/nrm2321 · External reference
10.1016/j.addr.2009.04.004
10.1016/j.addr.2009.04.004 · External reference
10.1073/pnas.0501507102
10.1073/pnas.0501507102 · External reference
10.1038/mt.2008.50
10.1038/mt.2008.50 · External reference
10.1089/hum.2013.200
10.1089/hum.2013.200 · External reference
10.1038/mt.2011.219
10.1038/mt.2011.219 · External reference
10.1093/hmg/ddv442
10.1093/hmg/ddv442 · External reference
10.1056/nejmoa1208760
10.1056/nejmoa1208760 · External reference
10.1038/cgt.2009.53
10.1038/cgt.2009.53 · External reference
10.1016/j.ymthe.2005.05.006
10.1016/j.ymthe.2005.05.006 · External reference
10.1016/j.bbrc.2006.02.141
10.1016/j.bbrc.2006.02.141 · External reference
10.1038/mtna.2016.7
10.1038/mtna.2016.7 · External reference
10.1038/gt.2017.14
10.1038/gt.2017.14 · External reference
RNAi mechanisms in Huntington's disease therapy: siRNA versus shRNA
10.1186/s40035-017-0101-9 · 2017 · External reference
10.1089/oli.1.2000.10.117
10.1089/oli.1.2000.10.117 · External reference
10.1146/annurev.pharmtox.010909.105654
10.1146/annurev.pharmtox.010909.105654 · External reference
10.1016/j.neuron.2012.05.009
10.1016/j.neuron.2012.05.009 · External reference
Alpha-synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease
2019 · External reference
10.1016/j.omtn.2017.08.002
10.1016/j.omtn.2017.08.002 · External reference
Amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides targeting alpha-synuclein as a novel therapy for Parkinson's disease
10.1038/s41598-019-43772-9 · 2019 · External reference
An endogenous peptide marker differentiates SOD1 stability and facilitates pharmacodynamic monitoring in SOD1 amyotrophic lateral sclerosis
10.1172/jci.insight.122768 · 2019 · External reference
10.1016/s1474-4422(13)70061-9
10.1016/s1474-4422(13)70061-9 · External reference
10.1212/wnl.0000000000002445
10.1212/wnl.0000000000002445 · External reference
10.1016/s0140-6736(16)31408-8
10.1016/s0140-6736(16)31408-8 · External reference
De Vivo, and I.-C.I.-C.S. Groups, Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1/2 studies
10.1212/wnl.0000000000007527 · 2019 · External reference
Eteplirsen in the treatment of Duchenne muscular dystrophy
10.2147/dddt.s97635 · 2017 · External reference
10.1212/nxg.0000000000000323
10.1212/nxg.0000000000000323 · External reference
10.1358/dot.2017.53.5.2646003
10.1358/dot.2017.53.5.2646003 · External reference
Huntington's Disease clinical trials corner: august 2018
10.3233/jhd-189003 · 2018 · External reference
Phase 1–2a, Targeting Huntingtin Expression in Patients with Huntington's Disease
10.1056/nejmoa1900907 · 2019 · External reference
The effects of 2'-O-methoxyethyl oligonucleotides on renal function in humans
10.1089/nat.2017.0693 · 2018 · External reference
10.1007/s00702-018-1910-4
10.1007/s00702-018-1910-4 · External reference
Molecular imaging markers to track huntington's disease pathology
10.3389/fneur.2017.00011 · 2017 · External reference
Extrafield activity shifts the place field center of mass to encode aversive experience
10.1523/eneuro.0423-17.2019 · 2019 · External reference
